HKUBio - Hong Kong Universal Biologicals Company Limited
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Other R&D services
Hong Kong Universal Biologicals (HKUBio) pioneers DelNS1 Live Attenuated Influenza viral vector vaccine technology, offering advanced intranasal immunization against respiratory diseases like flu and COVID-19. Its approach enhances both systemic and mucosal immunity, surpassing traditional intramuscular vaccines and setting new standards for respiratory disease prevention. Current Vaccine Candidates:
- COVID-19 Intranasal Vaccine
- Seasonal Influenza Vaccine
- Avian Flu H5N1 Vaccine
- Respiratory Syncytial Virus (RSV) Vaccine
- Flu-COVID Bivalent Vaccine
· Platform: Live attenuated influenza viral vector with NS1 gene deletion for enhanced safety and immunogenicity
- New Vaccine within 3 weeks: a vaccine platform that has completed proof of concept for influenza and COVID-19,
- Effectiveness:
- Full IP protected and Collaborations: Partnered with Xiamen University and Beijing Wantai Biopharm to develop and gain emergency approval for the world’s first intranasal COVID-19 vaccine in mainland China.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}